Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effectiveness of Motixafortide and G-CSF for Stem Cell Collection in Patients with Multiple Myeloma

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition called Multiple Myeloma, which is a type of cancer that affects the blood cells in the bone marrow. The study is investigating a treatment that combines a medication called BL-8040 (also known as Motixafortide) with another drug called G-CSF. The purpose of this study is to see if this combination is better than using a placebo with G-CSF for helping the body produce more stem cells. These stem cells are important for a procedure called autologous transplantation, where a patient's own stem cells are collected and then given back to them to help treat the disease.

Participants in the study will receive either the combination of BL-8040 and G-CSF or a placebo with G-CSF. The study will be conducted in a way that neither the participants nor the researchers know who is receiving which treatment, to ensure unbiased results. The treatment involves injections, and the study will monitor how well the body can produce and collect stem cells over a couple of sessions. The goal is to collect a certain number of stem cells that are needed for the transplantation process.

The study will also look at how quickly the body recovers after the transplantation, focusing on how fast the blood cells return to normal levels. This includes checking the recovery of white blood cells and platelets, which are important for fighting infections and preventing bleeding. The study will follow participants for several months after the transplantation to see how well the stem cells continue to work in the body. This research aims to improve the treatment process for patients with Multiple Myeloma by making stem cell collection more effective and efficient.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be informed about the trial's purpose and procedures. Consent is required before participation begins.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility. This includes a review of medical history and a physical examination.

  3. Step 3

    Medication administration

    The patient will receive a single dose of either BL-8040 or a placebo. This is administered as a subcutaneous injection.

    The injection is prepared by reconstituting a lyophilized powder with 2 mL of 0.45% Sodium Chloride.

  4. Step 4

    G-CSF administration

    The patient will also receive G-CSF (Granulocyte-Colony Stimulating Factor) to help mobilize stem cells. The dosage and frequency will be determined by the study protocol.

  5. Step 5

    Apheresis sessions

    Up to two apheresis sessions will be conducted to collect stem cells. The goal is to collect at least 6.0 x 10^6 CD34+ cells per kilogram of body weight.

  6. Step 6

    Monitoring and follow-up

    The patient will be monitored for any side effects or reactions to the treatment. Regular follow-up visits will be scheduled to assess the patient's health and the efficacy of the treatment.

  7. Step 7

    Transplantation preparation

    If sufficient stem cells are collected, the patient will be prepared for autologous hematopoietic cell transplantation.

  8. Step 8

    Post-transplantation monitoring

    After transplantation, the patient will be monitored for engraftment and recovery. This includes checking for neutrophil and platelet engraftment and assessing graft durability at various intervals up to 12 months post-transplantation.

Who can join the trial?

16 criteria

  • Patients must be between the ages of 18 and 78 years.
  • Women who can have children must agree to use two methods of effective birth control. This includes one barrier method like a condom or diaphragm, combined with a spermicide, and one hormonal method like birth control pills or patches. Alternatively, they can use a highly effective method like an intrauterine device (IUD) or have a partner who has had a vasectomy. These methods must be used before joining the study and continue for 30 days after the last dose of the study treatment.
  • Men must agree to use an effective method of birth control starting from the first day of G-CSF administration until 30 days after the last dose of the study drug.
  • Patients must sign a consent form to participate in the study.
  • Patients must have a confirmed diagnosis of **Multiple Myeloma** before joining the study.
  • Patients must wait at least one week (7 days) after their last cycle of chemotherapy before receiving the first dose of G-CSF for mobilization.
  • Patients must be eligible for **Autologous Hematopoietic Stem Cell Transplantation** as determined by the study doctor.
  • Patients should be in their first or second complete response (CR) or partial response (PR) to treatment.
  • Patients must have an **ECOG performance status** of 0 or 1, which means they are fully active or have some symptoms but do not need bed rest during the day.
  • Patients must have adequate organ function, which includes:
    • White blood cell counts above a certain level.
    • Neutrophil count above a certain level.
    • Platelet count above a certain level.
    • **Renal function** with a **GFR** value of at least 15 mL/min/1.73^2.
    • **Liver function** with **ALT** and **AST** levels not more than 2.5 times the upper limit of normal, and **Total Bilirubin** not more than 2 times the upper limit unless the patient has Gilbert disease.
    • **Coagulation tests** with **INR** or **PT** not more than 1.5 times the upper limit unless the patient is on blood thinners, as long as the tests are within the therapeutic range.
    • Women who can have children must have a negative pregnancy test before starting the study and within 72 hours before the first administration of G-CSF.

Who cannot join the trial?

10 criteria

  • Patients who have a different type of cancer other than Multiple Myeloma. Multiple Myeloma is a type of blood cancer that affects plasma cells in the bone marrow.
  • Patients who have not been diagnosed with Multiple Myeloma.
  • Patients who are not eligible for autologous hematopoietic cell transplantation. This is a procedure where a patient's own stem cells are collected, stored, and then given back to them after intensive treatment.
  • Patients who are unable to undergo the process of stem cell mobilization. This is a procedure to increase the number of stem cells in the bloodstream for collection.
  • Patients who have medical conditions that would make it unsafe to participate in the study.
  • Patients who are not within the specified age range for the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are unable to comply with the study procedures.
  • Patients who have participated in another clinical trial recently.
  • Patients who have allergies or reactions to the study medications.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • BL-8040

    is an experimental medication being tested for its ability to help move stem cells from the bone marrow into the bloodstream. This process is important for collecting stem cells that can be used later in a transplant. In this study, BL-8040 is being combined with another medication to see if it can improve the collection of stem cells in patients with multiple myeloma.

  • G-CSF

    (Granulocyte-Colony Stimulating Factor) is a medication that helps the body produce more white blood cells. It is commonly used to help move stem cells from the bone marrow into the bloodstream, making it easier to collect them for a transplant. In this study, G-CSF is used in combination with BL-8040 to see if this combination is more effective than using G-CSF alone.

What is already known about the treatment

  • BL-8040

    This medication is administered through injection and is currently being studied in clinical trials for its effectiveness in mobilizing stem cells for transplantation in multiple myeloma patients. It is not yet widely used in standard medical practice but shows promise in medical literature. The main therapeutic indication is to aid in the collection of stem cells for autologous transplantation. At the molecular level, BL-8040 works by blocking certain receptors on the surface of cells, which helps release stem cells from the bone marrow into the bloodstream. It is classified as a chemokine receptor antagonist.

  • G-CSF

    This medication is typically administered via injection and is well-established in medical practice for stimulating the production of white blood cells. It is commonly used to mobilize stem cells for transplantation in patients with multiple myeloma. G-CSF works by binding to specific receptors on the surface of bone marrow cells, promoting the growth and release of stem cells into the bloodstream. It is classified as a growth factor.

Investigated diseases

Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. These cancerous plasma cells multiply rapidly, leading to an overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can lead to bone pain, fractures, anemia, and increased susceptibility to infections. The accumulation of these abnormal cells can also interfere with the production of normal blood cells, leading to various complications. Over time, the disease can cause significant damage to the bones and other organs, impacting overall health and quality of life.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-511953-23-00Protocol codeBL-8040.SCM.301Estimated enrolment122 patientsSponsorBioline Rx Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.